New Mesothelioma Clinical Trial Involves Keytruda
Standard-of-care treatment for malignant mesothelioma could change significantly depending upon the results of an upcoming clinical trial of two immunotherapy agents used in combination with chemotherapy. The clinical trial will involve pembrolizumab, also known by the brand name Keytruda and its synergy with ONCOS-102, a lesser-known, genetically modified adenovirus. Individually, both have shown modest efficacy for mesothelioma […]